115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
恶唑烷酮类药物用于 MRSA 相关复杂性皮肤和软组织感染的卫生技术评估
Authors Zhao Y , Huang B, Yang Z, Kuang H, Chen J
Received 4 July 2025
Accepted for publication 2 January 2026
Published 9 January 2026 Volume 2026:20 551561
DOI https://doi.org/10.2147/DDDT.S551561
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Georgios Panos
Yucheng Zhao, Baisen Huang, Zunchang Yang, Hongjie Kuang, Jisheng Chen
Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China
Correspondence: Jisheng Chen, Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, People’s Republic of China, Tel +86 020-87622305, Email cjslym@163.com
Purpose: This study aims to provide a reference for the introduction and utilization of oxazolidinone drugs in medical institutions, based on the authoritative Chinese guideline, Rapid Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (2nd Edition) (Rapid Guideline).
Patients and Methods: Based on the Rapid Guideline, this study conducted a comprehensive literature search across relevant databases, including the China National Knowledge Infrastructure (CNKI), PubMed, Embase, and the Cochrane Library, as well as drug labels and relevant clinical guidelines. A health technology assessment (HTA) was then performed on three oxazolidinone drugs across five dimensions: pharmaceutical properties, efficacy, safety, economy, and other attributes.
Results: The final evaluation results from highest to lowest were tedizolid (83.52 points), linezolid (80.02 points), and contezolid (72.79 points). The evaluation results of tedizolid across the five dimensions were as follows: pharmaceutical properties (25.5 points), efficacy (25 points), safety (17.5 points), economy (9.02 points), and other attributes (6.5 points). For linezolid, the scores were pharmaceutical properties (25 points), efficacy (25 points), safety (18 points), economy (5.02 points), and other attributes (7 points). For contezolid, the scores were pharmaceutical properties (24 points), efficacy (22 points), safety (18.5 points), economy (4.29 points), and other attributes (4 points).
Conclusion: Based on the comprehensive evaluation across five key dimensions, the recommended prioritization of oxazolidinone antibiotics is as follows: tedizolid, linezolid, and contezolid. The ranking was primarily driven by tedizolid’s once-daily dosing and lowest total course cost, linezolid’s pediatric indication and widespread availability, and contezolid’s superior safety profile, although its overall score was limited by higher cost and lack of guideline recommendations. This study recommends the selection of tedizolid, linezolid, and contezolid for use in medical institutions during the introduction and application of oxazolidinone antibiotics.
Keywords: oxazolidinone drugs, complicated SSTIs, MRSA, health technology assessment
Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China
Correspondence: Jisheng Chen, Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, People’s Republic of China, Tel +86 020-87622305, Email cjslym@163.com
Purpose: This study aims to provide a reference for the introduction and utilization of oxazolidinone drugs in medical institutions, based on the authoritative Chinese guideline, Rapid Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (2nd Edition) (Rapid Guideline).
Patients and Methods: Based on the Rapid Guideline, this study conducted a comprehensive literature search across relevant databases, including the China National Knowledge Infrastructure (CNKI), PubMed, Embase, and the Cochrane Library, as well as drug labels and relevant clinical guidelines. A health technology assessment (HTA) was then performed on three oxazolidinone drugs across five dimensions: pharmaceutical properties, efficacy, safety, economy, and other attributes.
Results: The final evaluation results from highest to lowest were tedizolid (83.52 points), linezolid (80.02 points), and contezolid (72.79 points). The evaluation results of tedizolid across the five dimensions were as follows: pharmaceutical properties (25.5 points), efficacy (25 points), safety (17.5 points), economy (9.02 points), and other attributes (6.5 points). For linezolid, the scores were pharmaceutical properties (25 points), efficacy (25 points), safety (18 points), economy (5.02 points), and other attributes (7 points). For contezolid, the scores were pharmaceutical properties (24 points), efficacy (22 points), safety (18.5 points), economy (4.29 points), and other attributes (4 points).
Conclusion: Based on the comprehensive evaluation across five key dimensions, the recommended prioritization of oxazolidinone antibiotics is as follows: tedizolid, linezolid, and contezolid. The ranking was primarily driven by tedizolid’s once-daily dosing and lowest total course cost, linezolid’s pediatric indication and widespread availability, and contezolid’s superior safety profile, although its overall score was limited by higher cost and lack of guideline recommendations. This study recommends the selection of tedizolid, linezolid, and contezolid for use in medical institutions during the introduction and application of oxazolidinone antibiotics.
Keywords: oxazolidinone drugs, complicated SSTIs, MRSA, health technology assessment